osteoporosis

The FDA has approved Amgen's osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication to prevent complications such as fractures and bone pain among those patients could boost the drug's sales by billions.

Osteoporosis drugs taken to prevent bone fracture may cause rare, but critical, fractures of their own, the Food and Drug Administration announced today in a warning to consumers. The agency also noted it would require a change to the medications' labels, which currently don't indicate that risk....

Amgen, the world's largest biotechnology company, reported fourth-quarter results that missed Wall Street's expectations, as a 2% increase in sales failed to translate into a stronger bottom line.

Drugmaker Amgen (AMGN) did not win the Food & Drug Administration's approval on Monday for its experimental osteoporosis treatment denosumab. Amgen, based in Thousand Oaks, Calif., had been banking on the drug's approval for company growth, but the FDA asked for more information before making a...

No doubt, Amgen (AMGN) and its investors would have liked the U.S. Food and Drug Administration's health panel proceedings to have gone differently. The good news coming out of the panel, held on Thursday, was that Amgen's highly anticipated bone drug, denosumab, benefits patients with...